Liposomal irinotecan with chemo after pancreatic cancer surgery
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a combination of three chemotherapy medicines (liposomal irinotecan, oxaliplatin, and tegafur) given after surgery to remove pancreatic cancer. The goal is to see if this treatment helps prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had surgery to remove pancreatic cancer and all visible cancer was removed (R0 or R1 resection).
- You are generally active and can take care of yourself (ECOG 0 or 1).
- Your doctor expects you to live at least 6 more months.
- You are able to eat by mouth and do not have a stomach emptying problem after surgery.
- You do not have moderate or severe diarrhea (4 or more loose stools per day).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well a specific type of chemotherapy called irinotecan hydrochloride liposome works in people with pancreatic cancer. Researchers want to understand its effects in real-world settings, which may help doctors choose the best treatment for patients.
This trial tests a combination of chemotherapy drugs given before and after surgery for pancreatic cancer that is considered high-risk but removable. The goal is to see if this approach can improve outcomes for patients with this type of cancer.
This trial tests a new combination of chemotherapy drugs for people whose pancreatic cancer has progressed after prior irinotecan treatment. The goal is to see if this new combination can help shrink tumors or slow the cancer's growth.
This trial tests a combination of two chemotherapy drugs (irinotecan liposome and capecitabine) for people with pancreatic cancer that has spread or cannot be removed by surgery and has gotten worse after initial treatment. The goal is to see if this combination can help slow the disease.
This trial tests whether giving radiation therapy before a combination of two chemotherapy drugs (NALIRIFOX) is better than chemotherapy alone for people with pancreatic cancer that is on the edge of being removable. The goal is to see if adding radiation helps shrink the tumor enough to make surgery possible and improve outcomes.
This trial tests a combination of four drugs (liposomal irinotecan, 5-fluorouracil, oxaliplatin, and adebrelimab) given with radiation therapy before surgery for pancreatic cancer that can be surgically removed or is borderline removable. The goal is to shrink the tumor and improve the chances of successful surgery.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.